The British journal of dermatology
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Psoriasis is a chronic disease that significantly diminishes the health-related quality of life (HRQOL). Infliximab is a chimeric, tumour necrosis factor alpha monoclonal antibody that has been shown to improve the signs and symptoms of plaque psoriasis. ⋯ Infliximab induction therapy resulted in significant improvement in HRQOL in patients with severe psoriasis.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
Imiquimod is an immune response modifier that acts through toll-like receptor 7 to induce cytokine production and a subsequent innate and adaptive cell-mediated immune response. Clinical studies have demonstrated clinical and histological clearance of superficial basal cell carcinoma (sBCC) after treatment with imiquimod 5% cream. ⋯ Imiquimod 5% cream administered 7 x/week for 6 weeks is a safe and effective treatment for sBCC when compared with vehicle cream.
-
Pyoderma gangrenosum (PG) is frequently associated with constitutional symptoms as part of a nonspecific inflammatory response. However, extracutaneous discrete aseptic neutrophilic infiltrates are extremely rare. ⋯ His disease was extremely aggressive and was unresponsive to conventional immunosuppressive therapy. His cutaneous and extracutaneous PG cleared with infliximab and adalimumab.
-
Acne occurs in prepubertal individuals, teenagers and adults, and can have a devastating effect on self-esteem and social relationships. Whether an acne sufferer will seek treatment often depends, apart from the severity, on cultural and social aspects, which play a significant role in the attitude of the individuals and how they cope with the condition. Compliance with treatment regimen is an essential element in overall effectiveness of therapy. ⋯ The study demonstrates that a range of disease-related and social factors may influence compliance with treatment in acne. The inverse relationship between DLQI and Med Ad probably reflects the profound interaction of physical and psychological factors as well as perceived treatment failure.